ABSTRACT
Chlamydophila psittaci (C. psittaci) is an avian pathogen associated with systemic wasting disease in birds, as well as a public health risk. Although duck-related cases of psittacosis have been reported, the pathogenicity and shedding status of C. psittaci in ducks are unclear. In this study, we reported that C. psittaci (genotype A) is responsible for a disease outbreak characterized by poor laying performance and severe lesions in multiple organs of ducks. Oral administration of antibiotic, doxycycline, was found to effectively control the C. psittaci infection in laying ducks. Collectively, our new findings provide evidence that C. psittaci was the major pathogen responsible for the outbreak of this disease in ducks. In order to reduce economic losses incurred by this disease, effective control measures must be taken to prevent infection in laying duck farms.
Subject(s)
Chlamydophila psittaci/physiology , Ducks , Poultry Diseases/pathology , Psittacosis/pathology , Animals , Anti-Bacterial Agents/administration & dosage , China , Chlamydophila psittaci/classification , Chlamydophila psittaci/drug effects , Doxycycline/administration & dosage , Female , Poultry Diseases/drug therapy , Poultry Diseases/microbiology , Poultry Diseases/physiopathology , Psittacosis/drug therapy , Psittacosis/microbiology , Psittacosis/physiopathology , ReproductionABSTRACT
The obligate intracellular bacterium Chlamydia psittaci is the causative agent of psittacosis in birds and humans. The capability of this zoonotic pathogen to develop a persistent phase may serve a role in the chronicity of infections, in addition to the failure of antibiotic therapy or immunoprophylaxis. In the present study, a C. psittaci strain 6BC persistent infection cell model was induced using interferon (IFN)γ, alterations in the infectivity and morphology of the pathogen were analyzed, and the transcript profile of seven selected genes was analyzed. Following treatment with IFNγ, the infectivity of C. psittaci 6BC was decreased, the inclusion bodies appeared to be smaller, reticulate bodies were larger and the number of infectious elementary bodies was decreased compared with acute infection. In IFNγinduced persistently infected cells, the relative mRNA expression levels of the genes CPSIT0208, CPSIT0310, CPSIT0846, CPSIT0844 and CPSIT0594 were upregulated at 248 h postinfection (p.i.). The genes CPSIT0959 and CPSIT0057 were downregulated at 236 h p.i. The results of the present study advanced the understanding of C. psittaci persistent infection and demonstrated a number of previously unknown alterations in chlamydial gene expression, which may provide novel targets to further analyze this particular hostpathogen interaction.
Subject(s)
Chlamydophila psittaci/drug effects , Chlamydophila psittaci/genetics , Gene Expression Regulation, Bacterial/drug effects , Interferon-gamma/pharmacology , Psittacosis/microbiology , Transcription, Genetic , Cells, Cultured , Chlamydophila psittaci/ultrastructure , Fluorescent Antibody Technique , HeLa Cells , Host-Pathogen Interactions , HumansABSTRACT
Chlamydophila psittaci is an important intracellular pathogen. Persistent infection is an important state of the host-parasite interaction in this chlamydial infection, which plays a significant role in spreading the organism within animal populations and in causing chronic chlamydiosis and serious sequelae. In this study, a C. psittaci persistent infection cell model was induced by penicillin G, and real-time quantitative PCR was used to study the transcriptional levels of 10 C. psittaci genes (dnaA, dnaK, ftsW, ftsY, grpE, rpsD, incC, omcB, CPSIT_0846, and CPSIT_0042) in acute and penicillin-G-induced persistent infection cultures. Compared with the acute cultures, the penicillin-G-treated cultures showed a reduced chlamydial inclusion size and a significantly decreased number of elementary body particles. Additionally, some enlarged aberrant reticulate body particles were present in the penicillin- G-treated cultures but not the acute ones. The expression levels of genes encoding products for cell division (FtsW, FtsY) and outer membrane protein E encoding gene (CPSIT_0042) were downregulated (p < 0.05) from 6 h post-infection onward in the persistent infection cultures. Also from 6 h post-infection, the expression levels of DnaA, DnaK, IncC, RpsD, GrpE, and CPSIT_0846 were upregulated (p < 0.05); however, the expression level of OmcB in the persistent infection was almost the same as that in the acute infection (p > 0.05). These results provide new insight regarding molecular activities that accompany persistence of C. psittaci, which may play important roles in the pathogenesis of C. psittaci infection.
Subject(s)
Chlamydophila psittaci/drug effects , Chlamydophila psittaci/genetics , Epithelial Cells/microbiology , Gene Expression Profiling , Penicillin G/metabolism , HeLa Cells , Humans , Real-Time Polymerase Chain Reaction , Time FactorsABSTRACT
Chlamydia psittaci is a zoonotic bacterium with a wide host range that can cause respiratory disease in humans and cattle. In the present study, effects of treatment with macrolides and quinolones applied alone or in combination with rifampicin were tested in a previously established bovine model of respiratory C. psittaci infection. Fifty animals were inoculated intrabronchially at the age of 6-8 weeks. Seven served as untreated controls, the others were assigned to seven treatment groups: (i) rifampicin, (ii) enrofloxacin, (iii) enrofloxacin + rifampicin, (iv) azithromycin, (v) azithromycin + rifampicin, (vi) erythromycin, and (vii) erythromycin + rifampicin. Treatment started 30 hours after inoculation and continued until 14 days after inoculation (dpi), when all animals were necropsied. The infection was successful in all animals and sufficient antibiotic levels were detected in blood plasma and tissue of the treated animals. Reisolation of the pathogen was achieved more often from untreated animals than from other groups. Nevertheless, pathogen detection by PCR was possible to the same extent in all animals and there were no significant differences between treated and untreated animals in terms of local (i.e., cell count and differentiation of BALF-cells) and systemic inflammation (i.e. white blood cells and concentration of acute phase protein LBP), clinical signs, and pathological findings at necropsy. Regardless of the reduced reisolation rate in treated animals, the treatment of experimentally induced respiratory C. psittaci infection with enrofloxacin, azithromycin or erythromycin alone or in combination with rifampicin was without obvious benefit for the host, since no significant differences in clinical and pathological findings or inflammatory parameters were detected and all animals recovered clinically within two weeks.
Subject(s)
Anti-Bacterial Agents/pharmacology , Chlamydophila psittaci/drug effects , Fluoroquinolones/pharmacology , Macrolides/pharmacology , Psittacosis/drug therapy , Psittacosis/veterinary , Animals , Azithromycin/pharmacology , Cattle , Disease Models, Animal , Enrofloxacin , Erythromycin/pharmacology , Inflammation/drug therapy , Inflammation/microbiology , Male , Rifampin/pharmacologyABSTRACT
Antimicrobial treatment of chlamydial infections is known to be of limited efficacy. In this study, effects of doxycycline (D), usually the drug of choice, were compared with the combined therapy of doxycycline and rifampicin (R) in a bovine model of respiratory Chlamydia psittaci infection. After intrabronchial inoculation of the pathogen, 30 animals were assigned to five groups (n = 6 per group): untreated controls, monotherapy with D (5 mg kg(-1)day(-1) or 10 mg kg(-1)day(-1)), and combination therapy of D and R (600 mg day(-1)). Treatment continued until day 14 post inoculation (d.p.i.). Clinical signs, inflammatory markers, and pathological findings confirmed successful infection in all animals. Reisolation of the pathogen was possible in 4/6 untreated animals and in 4/12 animals treated with D alone until 4 d.p.i., but in none of the calves of the two D + R groups. Pathogen detection was possible in all animals without significant differences among groups. Severity of disease and time course of its resolution, assessed by clinical and pathological findings as well as inflammatory parameters, were not significantly different between untreated controls and calves receiving D alone or in combination with R. Regardless of the treatment regimen, all groups recovered clinically and cleared the infection within 2 weeks.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Chlamydophila psittaci/drug effects , Doxycycline/administration & dosage , Psittacosis/drug therapy , Rifampin/administration & dosage , Animals , Bronchoalveolar Lavage Fluid/chemistry , Bronchoalveolar Lavage Fluid/cytology , Cattle , Disease Models, Animal , Drug Therapy, Combination/methods , Lung/pathology , Male , Prospective Studies , Psittacosis/pathology , Severity of Illness Index , Time Factors , Treatment OutcomeABSTRACT
PURPOSE: To compare genome-wide DNA methylation profiles according to Chlamydophila psittaci (Cp) infection status and the response to doxycycline treatment in Korean patients with ocular adnexal extranodal marginal zone B-cell lymphoma (EMZL). METHODS: Twelve ocular adnexal EMZL cases were classified into two groups (six Cp-positive cases and six Cp-negative cases). Among the 12 cases, eight were treated with doxycycline as first-line therapy, and they were divided into two groups according to their response to the treatment (four doxy-responders and four doxy-nonresponders). The differences in the DNA methylation states of 27,578 methylation sites in 14,000 genes were evaluated using Illumina bead assay technology. We also validated the top-ranking differentially methylated genes (DMGs) with bisulfite direct sequencing or pyrosequencing. RESULTS: The Infinium methylation chip assay revealed 180 DMGs in the Cp-positive group (74 hypermethylated genes and 106 hypomethylated genes) compared to the Cp-negative group. Among the 180 DMGs, DUSP22, which had two significantly hypomethylated loci, was validated, and the correlation was significant for one CpG site (Spearman coefficient=0.6478, p=0.0262). Regarding the response to doxycycline treatment, a total of 778 DMGs were revealed (389 hypermethylated genes and 336 hypomethylated genes in the doxy-responder group). In a subsequent replication study for representative hypomethylated (IRAK1) and hypermethylated (CXCL6) genes, the correlation between the bead chip analysis and pyrosequencing was significant (Spearman coefficient=0.8961 and 0.7619, respectively, p<0.05). CONCLUSIONS: Ocular adnexal EMZL showed distinct methylation patterns according to Cp infection and the response to doxycycline treatment in this genome-wide methylation study. Among the candidate genes, DUSP22 has a methylation status that was likely attributable to Cp infection. Our data also suggest that the methylation statuses of IRAK1 and CXCL6 may reflect the response to doxycycline treatment.
Subject(s)
Chlamydophila psittaci/physiology , DNA Methylation/drug effects , Doxycycline/therapeutic use , Eye Neoplasms/genetics , Genome, Human/genetics , Lymphoma, B-Cell, Marginal Zone/genetics , Psittacosis/genetics , Adult , Aged , Chlamydophila psittaci/drug effects , Cluster Analysis , CpG Islands/genetics , DNA Methylation/genetics , DNA, Bacterial/genetics , Doxycycline/pharmacology , Eye Neoplasms/complications , Eye Neoplasms/drug therapy , Eye Neoplasms/microbiology , Female , Humans , Lymphoma, B-Cell, Marginal Zone/complications , Lymphoma, B-Cell, Marginal Zone/drug therapy , Lymphoma, B-Cell, Marginal Zone/microbiology , Male , Middle Aged , Psittacosis/complications , Psittacosis/drug therapy , Psittacosis/microbiology , Reproducibility of Results , Sequence Analysis, DNAABSTRACT
Clinically healthy homing pigeons may serve as an unnoticed reservoir for zoonotic bacteria. Hence, healthy pigeons from 172 different racing pigeon lofts were examined for Salmonella serovars, Campylobacter spp. and Chlamydophila (Chlamydia) psittaci. Two samplings were performed during the racing season in summer (1242 adult and 1164 juvenile pigeons) and two during winter (1074 adult pigeons). Each sampling was accompanied by a questionnaire to identify risk factors for positive lofts. Between 0.9 and 3.7%, 13.1 and 23.7%, and 12.8 and 42.6% of lofts were tested positive by cultural methods or polymerase chain reaction for Salmonella Typhimurium var. Copenhagen, Campylobacter jejuni and C. psittaci, respectively. The detection rate of C. psittaci was twice as high in samples from juvenile pigeons (29.1%) compared with samples from adult pigeons (15.0%, P <0.001). No other influence of age or season was detected. For the first time, pigeon-derived C. jejuni isolates (n=15) were characterized for their ability to invade human enterocytes in vitro. All isolates were invasive with an invasion index between 0.4 and 34.1 (human reference strain: average 11.3). Of 50 C. jejuni isolates tested for antimicrobial susceptibility, 46.0% were resistant to ciprofloxacin. All isolates were sensitive to erythromycin and tetracycline. The analysis of risk factors in association with the infection status of lofts for C. jejuni and C. psittaci suggested that biosecurity measures reduce the risk of infection. This study indicated a zoonotic potential of pigeon-derived C. jejuni. However, clinically healthy homing pigeons pose only a low risk for transmission of the investigated pathogens to humans.
Subject(s)
Bird Diseases/transmission , Campylobacter Infections/veterinary , Campylobacter jejuni/isolation & purification , Chlamydophila psittaci/isolation & purification , Columbidae/microbiology , Salmonella typhimurium/isolation & purification , Adult , Animals , Anti-Bacterial Agents/pharmacology , Bird Diseases/microbiology , Caco-2 Cells , Campylobacter Infections/microbiology , Campylobacter Infections/transmission , Campylobacter jejuni/drug effects , Campylobacter jejuni/genetics , Chlamydophila psittaci/drug effects , Chlamydophila psittaci/genetics , Ciprofloxacin/pharmacology , Erythromycin/pharmacology , Germany/epidemiology , Humans , Incidence , Male , Phenotype , Psittacosis/microbiology , Psittacosis/transmission , Psittacosis/veterinary , Risk Factors , Salmonella Infections, Animal/microbiology , Salmonella Infections, Animal/transmission , Salmonella typhimurium/drug effects , Salmonella typhimurium/genetics , Tetracycline/pharmacology , ZoonosesABSTRACT
To determine the efficacy of 21-day therapy with azithromycin and doxycycline in the treatment of experimental infection with Chlamydophila psittaci in cockatiels (Nymphicus hollandicus), 30 birds randomly assigned to 3 treatment groups and 1 control group were inoculated with C psittaci by combined intranasal and ocular routes. Morbidity, mortality, and results of polymerase chain reaction testing confirmed that infection was successful. Birds in group 1 (n = 8) received azithromycin at 40 mg/kg PO q48h for 21 days; in group 2 (n = 8), doxycycline at 35 mg/kg PO q24h for 21 days; in group 3 (n = 8), doxycycline at 35 mg/kg PO q24h for 45 days; and, in group 4 (controls; n = 6), no treatment. Six birds died either before or within 2 days of initiating treatment: 4 in the 3 treatment groups and 2 in the control group. Clinical signs resolved and mortality ceased 2-6 days after treatment was initiated in all treatment groups, whereas birds in the control group exhibited clinical signs for the duration of the study. Plasma doxycycline concentrations were measured during the treatment period and exceeded 1 microg/mL at all time points. The absence of clinical signs and mortality in the treatment groups, even after inducing an immunocompromised state with dexamethasone (3 mg/kg IM q24h for 5 days), starting on day 70 postinoculation, suggested that treatment resulted in elimination of the pathogen. After euthanasia of the remaining 24 birds, 23 of the carcasses were submitted for necropsy. Spleen and liver samples from the birds in all treatment and control groups were polymerase chain reaction negative for C psittaci nucleic acid, and organisms were not detected by Gimenez stain. No gross or histologic differences were observed in the livers and spleens of treated and untreated infected birds. Lesions consistent with avian chlamydiosis (hystiocytosis) were seen in all birds and were considered residual. In this study, a 21-day course of either doxycycline or azithromycin was effective in eliminating C psittaci infection in experimentally inoculated cockatiels. Additional studies are necessary to evaluate the efficacy of these treatments in naturally infected cockatiels as well as other species of birds.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Bird Diseases/drug therapy , Cockatoos , Doxycycline/therapeutic use , Psittacosis/veterinary , Animals , Anti-Bacterial Agents/administration & dosage , Azithromycin/administration & dosage , Bird Diseases/microbiology , Chlamydophila psittaci/drug effects , Doxycycline/administration & dosage , Drug Administration Schedule , Psittacosis/drug therapySubject(s)
Anti-Bacterial Agents/therapeutic use , Chlamydophila psittaci/drug effects , Doxycycline/therapeutic use , Lymphoma, B-Cell, Marginal Zone/drug therapy , Orbital Neoplasms/drug therapy , Psittacosis/drug therapy , Aged , Aged, 80 and over , Chlamydophila psittaci/isolation & purification , Chlamydophila psittaci/pathogenicity , Female , Humans , Lymphoma, B-Cell, Marginal Zone/complications , Lymphoma, B-Cell, Marginal Zone/microbiology , Lymphoma, B-Cell, Marginal Zone/pathology , Male , Middle Aged , Orbital Neoplasms/complications , Orbital Neoplasms/microbiology , Orbital Neoplasms/pathology , Psittacosis/complications , Remission Induction , Subcutaneous TissueABSTRACT
Azithromycin is a major drug used in the treatment and prophylaxis of chlamydial infections. Spontaneous azithromycin-resistant mutants of Chlamydia psittaci 6BC were isolated in vitro in the plaque assay at a frequency of about 10(-8). Isogenic clonal variants with A(2058)C, A(2059)G, or A(2059)C mutations in the unique 23S rRNA gene (Escherichia coli numbering system) displayed MICs for multiple macrolides (i.e., azithromycin, erythromycin, josamycin, and spiramycin) at least 100 times higher than those of the parent strain and were also more resistant to the lincosamide clindamycin. Chlamydia trachomatis L2 variants with a Gln-to-Lys substitution in ribosomal protein L4 at position 66 (E. coli numbering system), conferring an eightfold decrease in azithromycin and erythromycin sensitivities and a fourfold decrease in josamycin and spiramycin sensitivities, were isolated following serial passage in subinhibitory concentrations of azithromycin. Each mutation was stably maintained in the absence of selection but severely affected chlamydial infectivity, as determined by monitoring the development of each isolate over 46 h in the absence of selection, in pure culture or in 1:1 competition with the isogenic parent. Data in this study support the hypothesis that the mechanisms which confer high-level macrolide resistance in chlamydiae carry a prohibitive physiological cost and may thus limit the emergence of highly resistant clones of these important pathogens in vivo.
Subject(s)
Azithromycin/pharmacology , Chlamydophila psittaci/drug effects , Chlamydophila psittaci/genetics , Drug Resistance, Bacterial/genetics , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/genetics , DNA Mutational Analysis , Erythromycin/pharmacology , Gene Frequency , Microbial Sensitivity Tests , Mutation , Polymerase Chain Reaction , RNA, Ribosomal, 23S/genetics , Ribosomal Proteins/geneticsABSTRACT
The effect of ovotransferrin (ovoTF), human lactoferrin (hLF) and bovine lactoferrin (bLF) on the obligate intracellular pathogen Chlamydophila (Cp.) psittaci was evaluated using a model of Buffalo Green Monkey kidney (BGM) cells and HD11 chicken macrophages as artificial hosts. Firstly, the effect of transferrins on the infectivity of the bacteria was evaluated. Pre-incubation of Cp. psittaci with 0.5 to 5 mg/mL ovoTF prior to infecting BGM cells significantly lowered the infection rate (P < 0.05). For both lactoferrins, the infection rate could only be reduced with 5 mg/mL, albeit not significantly as compared to the infection rate created by the untreated bacteria. Secondly, transferrins were tested for their ability to influence bacterial adhesion and entry in HD11 cells. Maximal non-cytotoxic and non-bactericidal concentrations of 0.05 mg/mL ovoTF and 0.5 mg/mL hLF and bLF were used. Overall, ovoTF was more effective than human and bovine LF in inhibiting bacterial irreversible attachment and cell entry and the latter was accompanied by a dose-dependent reduction of actin recruitment at the bacterial entry site. However, once bacteria had entered HD11 cells, transferrins had apparently no effect on intracellular replication. The present findings suggest a possible role for transferrins and especially ovoTF, in preventing avian Cp. psittaci infections.
Subject(s)
Bacterial Adhesion/drug effects , Chlamydia Infections/veterinary , Chlamydophila psittaci/drug effects , Chlamydophila psittaci/physiology , Conalbumin/pharmacology , Lactoferrin/pharmacology , Macrophages/microbiology , Animals , Cell Line , Chickens , Chlamydia Infections/microbiology , Chlamydia Infections/prevention & control , Chlamydophila psittaci/growth & development , Chlamydophila psittaci/pathogenicity , Dose-Response Relationship, Drug , HumansABSTRACT
We studied zoonotic transmission of Chlamydophila psittaci in 39 breeding facilities for Psittaciformes (cockatoos, parrots, parakeets, lories) that frequently used antimicrobial drugs. Genotypes A or E/B were detected in 14.9% of humans at these facilities. Information on antimicrobial drug use in Psittaciformes and a C. psittaci vaccine are urgently required.
Subject(s)
Bird Diseases/transmission , Chlamydophila psittaci/pathogenicity , Psittaciformes/microbiology , Psittacosis/transmission , Psittacosis/veterinary , Zoonoses , Animal Husbandry , Animal Technicians , Animals , Anti-Bacterial Agents/therapeutic use , Bacterial Vaccines/administration & dosage , Belgium , Chlamydophila psittaci/drug effects , Chlamydophila psittaci/genetics , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , Disease Transmission, Infectious , Drug Resistance, Bacterial , Environmental Exposure , Feces/microbiology , Genotype , Humans , Occupational Diseases/epidemiology , Occupational Diseases/microbiology , Occupational Diseases/prevention & control , Psittacosis/drug therapyABSTRACT
A total of 18 chlamydial isolates from various psittacine birds, one isolate from a domestic pigeon and one isolate from a Pekin duck were isolated in continuous Buffalo Green Monkey (BGM) kidney cell cultures. All 20 isolates were identified by nested multiplex polymerase chain reaction as Chlamydophila psittaci. These isolates were multiplied to high titres and subsequently tested for in vitro sensitivity against two tetracyclines (chlortetracycline and doxycycline) and two quinolones (enrofloxacin and difloxacin) at concentrations of 0.0, 0.25, 0.50, 1.00, and 10.00 microg/ml. Replication of chlamydia in BGM cell cultures is assayed on the basis of formation of intracytoplasmic inclusions that are visualized by Giménez staining. All isolates, although to variable degrees, are sensitive to all four drugs. The number of chlamydial inclusions decreases gradually over a broad range of increasing concentrations of the drugs. The variation in the number of inclusions between isolates is remarkably high for chlortetracycline less for doxycycline and minimal for both fluoroquinolones, the enrofloxacin and difloxacin. The decline in numbers of inclusions is highly dose-dependend and the observed reduction stretches over a wide range of drug dilutions. Therefore, it is proposed to calculate drug sensitivity values in terms of inhibitory concentration 50%, (IC5). Its calculation includes all tested drug dilutions instead of the hitherto more common minimal inhibitory concentration, MIC, which is based on results of serial dilution tests for cell-free growing bacteria. Using a logistic regression model for the calculation of the inhibitory concentration 50% of all 20 chlamydial isolates, the IC50 is 0.807 microg/ml for tetracycline, 0.497 microg/ml for doxycycline, 0.180 microg/ml for enrofloxacin and 0.168 microg/ml for difloxacin. Complete prevention of inclusion formation was already seen for enrofloxacin at a concentration of 1.0 microg/ml in 12 out of 20 and for difloxacin in 5 out of 20 isolates whereas more than 10 microg/mI chlortetracycline is needed in 15 out of 20 isolates and for doxycycline 9 out of 20 isolates yielded inclusions at 10 microg/ml.
Subject(s)
Anti-Bacterial Agents/pharmacology , Bird Diseases/microbiology , Chlamydophila psittaci/drug effects , Psittacosis/veterinary , Animals , Bird Diseases/drug therapy , Birds , Cells, Cultured , Chlamydophila psittaci/growth & development , Chlortetracycline/pharmacology , Ciprofloxacin/analogs & derivatives , Ciprofloxacin/pharmacology , Dose-Response Relationship, Drug , Doxycycline/pharmacology , Enrofloxacin , Fluoroquinolones/pharmacology , Inhibitory Concentration 50 , Microbial Sensitivity Tests/veterinary , Psittacosis/drug therapy , Psittacosis/microbiologySubject(s)
Anti-Bacterial Agents/therapeutic use , Antineoplastic Agents/therapeutic use , Chlamydophila psittaci/drug effects , Chlamydophila psittaci/isolation & purification , Doxycycline/therapeutic use , Lymphoma, B-Cell, Marginal Zone/microbiology , Orbital Neoplasms/microbiology , Psittacosis/drug therapy , Clinical Trials as Topic , DNA, Bacterial/isolation & purification , Humans , Lymphoma, B-Cell, Marginal Zone/drug therapy , Multicenter Studies as Topic , Orbital Neoplasms/drug therapy , Prevalence , Prospective StudiesABSTRACT
BACKGROUND: An association between ocular adnexal MALT lymphoma (OAL) and Chlamydia psittaci (Cp) infection has been proposed, and recent reports suggest that doxycycline treatment causes tumor regression in patients with Cp-related OAL. The effectiveness of doxycycline treatment in Cp-negative OAL has not been tested. METHODS: In a prospective trial, 27 OAL patients (15 newly diagnosed and 12 having experienced relapse) were given a 3-week course of doxycycline therapy. Objective lymphoma response was assessed by computerized tomography scans or magnetic resonance imaging at 1, 3, and 6 months after the conclusion of therapy and every 6 months during follow-up. Cp infection in patients was determined by touchdown enzyme time-release polymerase chain reaction (TETR-PCR). Statistical tests were two-sided. RESULTS: Eleven patients were Cp DNA-positive and 16 were Cp DNA negative. Doxycycline was well tolerated. At a median follow-up of 14 months, lymphoma regression was complete in six patients, and a partial response (> or = 50% reduction of all measurable lesions) was observed in seven patients (overall response rate [complete and partial responses] = 48%). Lymphoma regression was observed in both Cp DNA-positive patients (seven of 11 experienced regression) and Cp DNA-negative patients (six of 16 experienced regression) (64% versus 38%; P = .25, Fisher's exact test). The three patients with regional lymphadenopathies and three of the five patients with bilateral disease achieved objective response. In relapsed patients, response was observed both in previously irradiated and nonirradiated patients. The 2-year failure-free survival rate among the doxycycline-treated patients was 66% (95% confidence interval = 54 to 78), and 20 of the 27 patients were progression free. CONCLUSIONS: Doxycycline is a fast, safe, and active therapy for Cp DNA-positive OAL that was effective even in patients with multiple failures involving previously irradiated areas or regional lymphadenopathies. The responses observed in PCR-negative OAL may suggest a need for development of more sensitive methods for Cp detection and investigation of the potential role of other doxycycline-sensitive bacteria.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Antineoplastic Agents/therapeutic use , Chlamydophila psittaci/drug effects , Doxycycline/therapeutic use , Lymphoma, B-Cell, Marginal Zone/drug therapy , Orbital Neoplasms/drug therapy , Psittacosis/drug therapy , Adult , Aged , Chlamydophila psittaci/isolation & purification , DNA, Bacterial/isolation & purification , Disease-Free Survival , Female , Follow-Up Studies , Humans , Lymphoma, B-Cell, Marginal Zone/microbiology , Lymphoma, B-Cell, Marginal Zone/pathology , Male , Middle Aged , Neoplasm Recurrence, Local/drug therapy , Orbital Neoplasms/microbiology , Orbital Neoplasms/pathology , Polymerase Chain Reaction , Prospective Studies , Psittacosis/complications , Treatment OutcomeABSTRACT
The obligatory intracellular bacterium Chlamydophila psittaci is the causative agent of psittacosis in birds and humans. The capability of this zoonotic pathogen to develop a persistent phase is likely to play a role in chronicity of infections, as well as in failure of antibiotic therapy and immunoprophylaxis. To elucidate three different in vitro models for transition of C. psittaci to persistence (iron depletion, penicillin G treatment, and gamma interferon [IFN-gamma] exposure), a set of 27 genes was examined by mRNA expression analysis using quantitative real-time PCR. While the phenotypical characteristics were the same as in other chlamydiae, i.e., aberrant morphology of reticulate bodies, loss of cultivability, and rescue of infectivity upon removal of inducers, the transcriptional response of C. psittaci to persistence-inducing factors included several new and distinctive features. Consistent downregulation of membrane proteins, chlamydial sigma factors, cell division protein, and reticulate body-elementary body differentiation proteins from 24 h postinfection onward proved to be a general feature of C. psittaci persistence. However, other genes displayed considerable variations in response patterns from one model to another, which suggests that there is no persistence model per se. In contrast to results for Chlamydia trachomatis, late shutdown of essential genes in C. psittaci was more comprehensive with IFN-gamma-induced persistence, which is probably due to the absence of a functional tryptophan synthesis operon.
Subject(s)
Bacterial Proteins/metabolism , Chlamydophila psittaci/pathogenicity , Gene Expression Regulation, Bacterial , Transcription, Genetic , Animals , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/genetics , Cell Line , Chlamydophila psittaci/drug effects , Chlamydophila psittaci/growth & development , Chlamydophila psittaci/ultrastructure , Deferoxamine/pharmacology , Humans , Immunohistochemistry , Interferon-gamma/pharmacology , Penicillin G/pharmacology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Siderophores/pharmacology , VirulenceABSTRACT
Rifalazil and other benzoxazinorifamycins (new chemical entities [NCEs]) are rifamycins that contain a distinct planar benzoxazine ring. Rifalazil has excellent antibacterial activity, high intracellular levels and high tissue penetration, which are attributes that favour its use in treating diseases caused by the obligate intracellular pathogens of the genus Chlamydia. Recent studies have shown that rifalazil has efficacy in the treatment of human sexually transmitted disease caused by Chlamydia trachomatis. The extraordinary potency of rifalazil and other NCEs, such as ABI-0043, extends to the related microorganism, C. pneumoniae, a respiratory pathogen that can disseminate and persist chronically in the vasculature, resulting in increased plaque formation in animal studies. A pivotal clinical trial with rifalazil has been initiated for the treatment of peripheral arterial disease. Other opportunities include gastric ulcer disease caused by Helicobacter pylori and antibiotic-associated colitis caused by infection with Clostridium difficile in the colon. The NCEs could prove to be valuable as follow-on compounds in these indications, as rifampin replacements in antibacterial combination therapy or as stand-alone topical antibacterials (e.g., to treat acne). Neither rifalazil nor NCEs appear to induce the cytochrome P450 3A4, an attribute of rifampin that can result in adverse events due to drug-drug interactions.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Atherosclerosis/drug therapy , Chlamydia Infections/drug therapy , Coronary Artery Disease/drug therapy , Rifamycins/therapeutic use , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacokinetics , Atherosclerosis/microbiology , Chlamydia Infections/microbiology , Chlamydia trachomatis/drug effects , Chlamydia trachomatis/isolation & purification , Chlamydophila pneumoniae/drug effects , Chlamydophila pneumoniae/isolation & purification , Chlamydophila psittaci/drug effects , Chlamydophila psittaci/isolation & purification , Coronary Artery Disease/microbiology , Disease Models, Animal , Drug Administration Schedule , Drug Evaluation, Preclinical , Drug Resistance, Bacterial , Humans , Microbial Sensitivity Tests , Randomized Controlled Trials as Topic , Rifamycins/administration & dosage , Rifamycins/pharmacokineticsABSTRACT
The fitness cost of a resistance determinant is the primary parameter that determines its frequency in vivo. As a model for analysis of the impact of drug resistance mutations on the intracellular life cycle of Chlamydia spp., we studied the growth of four genetically defined spectinomycin-resistant (Spc(r)) clonal variants of Chlamydia psittaci 6BC isolated in the plaque assay. The development of each variant was monitored over 46 h postinfection in the absence of drug, either in pure culture or in 1:1 competition with the parent strain. Spc(r) mutations in the 16S rRNA gene at positions 1191 and 1193 were associated with a marked impairment of C.psittaci biological fitness, and the bacteria were severely out-competed by the wild-type parent. In contrast, mutations at position 1192 had minor effects on the bacterial life cycle, allowing the resistant isolates to compete more efficiently with the wild-type strain. Thus, mutations with a wide range of fitness costs can be selected in the plaque assay, providing a new strategy for prediction and monitoring of the emergence of antibiotic resistance in chlamydiae. So far, drug resistance has not been a serious threat for the treatment of chlamydial infections. Tetracycline is an effective antichlamydial drug that targets 16S rRNA. Attempts to isolate spontaneous tetracycline-resistant mutants of C. psittaci 6BC revealed a frequency <3 x 10(-9). We suggest that the rarity of genotypic antibiotic resistance among chlamydial clinical isolates reflects the deleterious effects of such mutations on the fitness of these obligate intracellular bacteria in the host.
Subject(s)
Anti-Bacterial Agents/pharmacology , Chlamydophila psittaci/drug effects , Mutation , RNA, Ribosomal, 16S/genetics , Spectinomycin/pharmacology , Alleles , Chlamydophila psittaci/genetics , Drug Resistance, Bacterial , Escherichia coli/genetics , Phenotype , Plasmids , Tetracycline ResistanceABSTRACT
Mutations in rRNA genes (rrn) that confer resistance to ribosomal inhibitors are typically recessive or weakly codominant and have been mostly reported for clinical strains of pathogens possessing only one or two rrn operons, such as Helicobacter pylori and Mycobacterium spp. An analysis of the genome sequences of several members of the Chlamydiaceae revealed that these obligate intracellular bacteria harbor only one or two sets of rRNA genes. To study the contribution of rRNA mutations to the emergence of drug resistance in the Chlamydiaceae, we used the sensitivities of Chlamydia trachomatis L2 (two rrn operons) and Chlamydophila psittaci 6BC (one rrn operon) to the aminoglycoside spectinomycin as a model. Confluent cell monolayers were infected in a plaque assay with about 10(8) wild-type infectious particles and then treated with the antibiotic. After a 2-week incubation time, plaques formed by spontaneous spectinomycin-resistant (Spc(r)) mutants appeared with a frequency of 5 x 10(-5) for C. psittaci 6BC. No Spc(r) mutants were isolated for C. trachomatis L2, although the frequencies of rifampin resistance were in the same range for both strains (i.e., 10(-7)). The risk of emergence of Chlamydia strains resistant to tetracyclines and macrolides, the ribosomal drugs currently used to treat chlamydial infections, is discussed.
Subject(s)
Anti-Bacterial Agents/pharmacology , Chlamydia trachomatis/drug effects , Chlamydophila psittaci/drug effects , DNA-Directed RNA Polymerases/genetics , Drug Resistance, Bacterial/genetics , Mutation , RNA, Ribosomal, 16S/genetics , Animals , Cells, Cultured , Chlamydia trachomatis/genetics , Chlamydia trachomatis/growth & development , Chlamydophila psittaci/genetics , Chlamydophila psittaci/growth & development , Humans , Mice , Microbial Sensitivity Tests/methods , Molecular Sequence Data , Rifampin/pharmacology , Sequence Analysis, DNA , Spectinomycin/pharmacologyABSTRACT
This study reports an extraordinarily severe and prolonged course of neuroornithosis with generalized status epilepticus as an initial symptom. Direct invasion of the central nervous system by Chlamydophila psittaci was confirmed by the demonstration of specific DNA in the patient's cerebrospinal fluid. The patient recovered slowly under administration of doxycycline.